Publications 2023

Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086

Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
Cancer Res Commun, 3 (2), 235-244
DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142

Publications 2022

Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK (2022)
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
Breast Cancer (Dove Med Press), 14, 25-39
DOI 10.2147/BCTT.S338404, PubMed 35256859

Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
AXL inhibition improves BRAF-targeted treatment in melanoma
Sci Rep, 12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208

Publications 2021

Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235

Normann LS, Aure MR, Leivonen SK, Haugen MH, Hongisto V, Kristensen VN, Mælandsmo GM, Sahlberg KK (2021)
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Sci Rep, 11 (1), 10893
DOI 10.1038/s41598-021-90385-2, PubMed 34035375

Tamhane T, Njenga RW, Burden RE, Bueth H, Maelandsmo GM, Haugen MH, Scott CJ, Brix K (2021)
Trafficking of Full-Length and N-Terminally Truncated Cathepsin B in Human Colorectal Carcinoma Cells
Appl. Sci.-Basel, 11 (24), 11936
DOI 10.3390/app112411936

Publications 2020

Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
DOI 10.3389/fonc.2020.590755, PubMed 33324562

Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Krauss S, Olberg DE, Waaler J, Klaveness J (2020)
Correction: Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
RSC Adv, 10 (9), 4927
DOI 10.1039/d0ra90007a, PubMed 35503286

Publications 2019

Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA (2019)
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Mol Cancer Ther, 19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265

Grinde MT, Hilmarsdottir B, Tunset HM, Henriksen IM, Kim J, Haugen MH, Rye MB, Mælandsmo GM, Moestue SA (2019)
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
Breast Cancer Res, 21 (1), 61
DOI 10.1186/s13058-019-1141-0, PubMed 31088535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lien VT, Kristiansen MK, Pettersen S, Haugen MH, Olberg DE, Waaler J, Klaveness J (2019)
Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
RSC Adv, 9 (63), 37092-37100
DOI 10.1039/c9ra08954c, PubMed 35539091

Lien VT, Pettersen S, Haugen MH, Olberg DE, Maelandsmo GM, Klaveness J (2019)
Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors
Arch Pharm (Weinheim), 352 (9), e1900101
DOI 10.1002/ardp.201900101, PubMed 31414521

Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562

Publications 2018

Prasmickaite L, Tenstad EM, Pettersen S, Jabeen S, Egeland EV, Nord S, Pandya A, Haugen MH, Kristensen VN, Børresen-Dale AL, Oslo Breast Cancer Research Consortium (OSBREAC), Engebråten O, Maelandsmo GM (2018)
Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4
Mol Oncol, 12 (9), 1540-1558
DOI 10.1002/1878-0261.12319, PubMed 29741811

Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L (2018)
Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment
Cancer Lett, 439, 1-13
DOI 10.1016/j.canlet.2018.09.023, PubMed 30240588

Publications 2017

Lunde NN, Haugen MH, Bodin Larsen KB, Damgaard I, Pettersen SJ, Kasem R, Rut W, Drag M, Poreba M, Johansen HT, Solberg R (2017)
Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions
Biochimie, 139, 27-37
DOI 10.1016/j.biochi.2017.05.009, PubMed 28528272

Publications 2016

Dahl JA, Jung I, Aanes H, Greggains GD, Manaf A, Lerdrup M, Li G, Kuan S, Li B, Lee AY, Preissl S, Jermstad I, Haugen MH, Suganthan R, Bjørås M, Hansen K, Dalen KT, Fedorcsak P, Ren B, Klungland A (2016)
Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition
Nature, 537 (7621), 548-552
DOI 10.1038/nature19360, PubMed 27626377

Hetland G, Eide DM, Tangen JM, Haugen MH, Mirlashari MR, Paulsen JE (2016)
The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse
PLoS One, 11 (12), e0167754
DOI 10.1371/journal.pone.0167754, PubMed 28002446

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
Oncotarget, 7 (15), 19997-20015
DOI 10.18632/oncotarget.7671, PubMed 26918352

Publications 2015

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
Clin Exp Metastasis, 32 (8), 755-67
DOI 10.1007/s10585-015-9742-1, PubMed 26349943

Tamhane T, Lllukkumbura R, Lu S, Maelandsmo GM, Haugen MH, Brix K (2015)
Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells
Biochimie, 122, 208-18
DOI 10.1016/j.biochi.2015.09.003, PubMed 26343556

Tamhane T, Wolters BK, Illukkumbura R, Maelandsmo GM, Haugen MH, Brix K (2015)
Construction of a plasmid coding for green fluorescent protein tagged cathepsin L and data on expression in colorectal carcinoma cells
Data Brief, 5, 468-75
DOI 10.1016/j.dib.2015.09.022, PubMed 26594658

Publications 2014

Brix K, McInnes J, Al-Hashimi A, Rehders M, Tamhane T, Haugen MH (2014)
Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges
Protoplasma, 252 (3), 755-74
DOI 10.1007/s00709-014-0730-0, PubMed 25398648

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510

Publications 2013

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
Nuclear legumain activity in colorectal cancer
PLoS One, 8 (1), e52980
DOI 10.1371/journal.pone.0052980, PubMed 23326369

Publications 2012

Smith R, Johansen HT, Nilsen H, Haugen MH, Pettersen SJ, Mælandsmo GM, Abrahamson M, Solberg R (2012)
Intra- and extracellular regulation of activity and processing of legumain by cystatin E/M
Biochimie, 94 (12), 2590-9
DOI 10.1016/j.biochi.2012.07.026, PubMed 22902879

Publications 2011

Haugen MH (2011)
Posttranslational modification and subcellular localization of metastasis-associated proteins
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 1119, 1 b. (flere pag.)
BIBSYS 112675808, ISBN 978-82-8264-022-0

Publications 2010

Berge G, Andersen K, Haugen MH, Maelandsmo GM (2010)
Comment on the Importance of S100A4 in regulation of MMP-13
J Biol Chem, 285 (53), le23; author reply le24
DOI 10.1074/jbc.L110.125898, PubMed 21186294

Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R (2010)
Cystatin E/M suppresses legumain activity and invasion of human melanoma
BMC Cancer, 10, 17
DOI 10.1186/1471-2407-10-17, PubMed 20074384

Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
Tumour Biol, 32 (1), 1-12
DOI 10.1007/s13277-010-0073-1, PubMed 20652782

Publications 2008

Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
BMC Cancer, 8, 172
DOI 10.1186/1471-2407-8-172, PubMed 18554396